We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Experts: More Transparency Needed in EMA New Drug Approval Process
Experts: More Transparency Needed in EMA New Drug Approval Process
April 15, 2010
The European Medicines Agency (EMA) should increase the transparency of its drug approval process by releasing substantial parts of drug dossiers to the
scientific community.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor